Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 13/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29784561 | 1.00 | STING1 (0.77) | STING1KDM4EMAPTHSD17B10HPGD | |
| SCHEMBL29784456 | 0.91 | STING1 (0.75) | STING1KDM4EMAPTHSD17B10HPGD | |
| SCHEMBL27185840 | 0.91 | STING1 (0.75) | STING1KDM4EMAPTHSD17B10HPGD | |
| SCHEMBL27185529 | 0.90 | STING1 (0.78) | STING1KDM4EMAPTHSD17B10HPGD | |
| SCHEMBL29784478 | 0.90 | STING1 (0.78) | STING1KDM4EMAPTHSD17B10HPGD | |
| SCHEMBL27185831 | 0.90 | STING1 (0.73) | STING1KDM4EMAPTHSD17B10HPGD | |
| SCHEMBL29784464 | 0.90 | STING1 (0.73) | STING1KDM4EMAPTHSD17B10HPGD | |
| SCHEMBL30829631 | 0.88 | STING1 (0.69) | STING1KDM4EMAPTHSD17B10HPGD | |
| SCHEMBL27185698 | 0.88 | STING1 (0.69) | STING1KDM4EMAPTHSD17B10HPGD | |
| SCHEMBL30829680 | 0.87 | STING1 (1.00) | STING1KDM4EMAPTHSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240109899-A1 | BENZOFURAN COMPOUNDS AS STING AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109899-A1 | BENZOFURAN COMPOUNDS AS STING AGONISTS | STING1, MAVS, IRF3 | STING1 1/4885KDM4E 2249/4885MAPT 4171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.